NeuroMo® Clinical Trials
-
In a Pilot study (clinical trial number: CT05295966), thirty five subjects with a medical diagnosis of cognitive impairment participated in 24 sessions (3/week) of a home-based cognitive-multisensory physical exercise program using NeuroMo. The results showed a statically significant improvement for dual-task tests after the NeuroMo training program, while the control group showed an impairment in the verbal fluency test.
-
Figure 1. Results from the dual-task tests: (a) Experimental group reduced significantly the dual task interference for the Gait and subtraction test after the training program; (b) Experimental group reduced significantly the dual task interference for the Gait and subtraction test after the training program, while the control group increased it significantly. After the program training, the experimental group was significantly better than the control group in the Gait and Verbal fluency test.
* Differences with pre (p < 0.05). # Differences with experimental group (p < 0.05)
-
A second study aimed at evaluating the effectiveness of NeuroMo training in people with Parkinson's disease showed improvement in the motor function of these patients e.g. gait and reaction time to a stepping choice exercise.
Our pilot data demonstrated the clinical value of NeuroMo and its effect on improving the cognitive and motor functions in dementia and Parkinson disease.
-
Figure2. The statistical analysis showed a significant improvement for gait at maximal speed (clinically significant), choice stepping reaction time, choice tapping reaction time and reaching speed in the Experimental Group without improvement sin the control group.
WHAT IS THE NEXT NEUROMO® CLINICAL TRIAL?
INFORMATION COMING SOON